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Abstract
Background: An imbalance in Matrix MetalloProteases (MMPs) and Tissue Inhibitors of MMPs (TIMPs) contributes
to Chronic Obstructive Pulmonary Disease (COPD) development. Longitudinal studies investigating Single
Nucleotide Polymorphisms (SNPs) in MMPs and TIMPs with respect to COPD development and lung function
decline in the general population are lacking.
Methods: We genotyped SNPs in MMP1 (G-1607GG), MMP2 (-1306 C/T), MMP9 (3 tagging SNPs), MMP12 (A-82G
and Asn357Ser) and TIMP1 (Phe124Phe and Ile158Ile) in 1390 Caucasians with multiple FEV1 measurements from a
prospective cohort study in the general population. FEV1 decline was analyzed using linear mixed effect models
adjusted for confounders. Analyses of the X-chromosomal TIMP1 gene were stratified according to sex. All
significant associations were repeated in an independent general population cohort (n = 1152).
Results: MMP2 -1306 TT genotype carriers had excess FEV1 decline (-4.0 ml/yr, p = 0.03) compared to wild type
carriers. TIMP1 Ile158Ile predicted significant excess FEV1 decline in both males and females. TIMP1 Phe124Phe
predicted significant excess FEV1 decline in males only, which was replicated (p = 0.10) in the second cohort. The
MMP2 and TIMP1 Ile158Ile associations were not replicated. Although power was limited, we did not find
associations with COPD development.
Conclusions: We for the first time show that TIMP1 Phe124Phe contributes to excess FEV1 decline in two
independent prospective cohorts, albeit not quite reaching conventional statistical significance in the replication
cohort. SNPs in MMPs evidently do not contribute to FEV1 decline in the general population.
Background
Chronic Obstructive Pulmonary Disease (COPD) is char-
acterized by chronic airway inflammation, associated with
extracellular matrix (ECM) degradation and loss of elastic
recoil of lung tissue. The Matrix Metalloprotease (MMP)
gene family is thought to participate in the excessive col-
lagenolytic and elastolytic activity that contributes to ECM
destruction. MMPs are a family of secreted and membrane
associated zinc-dependent endopeptidases, capable of
cleaving ECM and non-matrix proteins. Many studies
have shown that MMP1, MMP2, MMP9, MMP12 protein
and mRNA levels are higher in lung tissue and induced
sputum of COPD patients than of controls [1-6].
Proteolytic activities of the MMPs are normally tightly
controlled in several ways, e.g. by transcriptional regula-
tion, activation of latent zymogen and interaction with
endogenous inhibitors of MMPs, the Tissue Inhibitors of
MMPs (TIMPs). Especially the imbalance between MMPs
a n dT I M P sh a sb e e np r o p o s e dt op l a yam a j o rr o l ei n
ECM destruction and development of COPD, a pulmonary
disease strongly associated with smoking. While most
COPD patients have smoked, only a subset of smokers
develops COPD, and it is likely that the susceptibility to
smoking is genetically determined. It is thus reasonable
that genetic determinants of the balance between MMPs
and TIMPs contribute to COPD development.
Single nucleotide polymorphisms (SNPs) have been
described in the promoter regions of MMP1, MMP2,
MMP9 and MMP12 and they can alter their expression
levels [7-10]. Joos et al. showed that SNPs in the MMP1
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jects with fast FEV1 decline compared to subjects with no
FEV1 decline in a cohort of current smokers with mild to
moderate airway obstruction [11]. SNPs in MMP12 have
been variably associated with lung function, i.e. with
higher lung function in children with asthma and adult
smokers and additionally with a reduced risk of COPD in
adult smokers [12] and increased risk of severe COPD
[13]. A MMP9 promoter SNP has been associated with
emphysema in a case-control study in a Japanese popula-
tion [13]. and with COPD in a Chinese population [14]. In
contrast, the promoter SNP in MMP2, a biologically plau-
sible candidate for COPD, as well as TIMP1 and TIMP2
SNPs have not been studied in relation to COPD develop-
ment or FEV1 decline. Whereas TIMP2 does not contain
SNPs known to alter function or expression, two synon-
ymous TIMP1 SNPs in the gene region responsible for
binding and inactivating of MMP9 have been associated
with asthma [15]. Thus, given the role of TIMP proteins
in inhibiting effects of metalloproteases SNPs in these
genes can conceivably play a role in COPD development.
Unraveling the genetics of MMPs and TIMPs in
COPD development may identify subjects who may spe-
cifically benefit from novel treatments like synthetic
MMP inhibitors that effectively prevent smoke-induced
COPD in animal models. Therefore, we studied SNPs in
MMP1, MMP2, MMP9, MMP12,a n dTIMP1 and their
interaction in relation to accelerated FEV1 decline and
COPD development in a general population cohort. To
verify our findings, we investigated whether significant
associations could be replicated in an independent
cohort of the general population.
Methods
Subjects
We genotyped DNA from 1390 subjects of the Vlagt-
wedde/Vlaardingen cohort that participated in the last sur-
vey in 1989/1990 [16]. This general population-based
cohort of Caucasians of Dutch descent started in 1965 and
surveys were performed at three year intervals. At each
survey, lung function measurements were performed
using standardized protocols and questionnaires were
c o m p l e t e d( s e ea d d i t i o n a lf i l e1 ) .T h es e l e c t i o no ft h e
cohort and details of the study have been described pre-
viously [16]. The study protocol was approved by the local
university hospital’s medical ethics committee and partici-
pants gave written informed consent.
As a replication cohort we used data from a random
sample of 1152 subjects from the Doetinchem cohort,
which is part of the larger MORGEN study [17,18]. The
MORGEN study was a random sample of the general
population of the Netherlands. Participants of the Doe-
tinchem study underwent spirometry in 1994-1997 and 5
years later in 1999-2003. Characteristics of both study
populations are presented in table 1. We identified subjects
with COPD using the GOLD criteria (GOLD stage II or
higher, i.e. FEV1/VC< 70% and FEV1<80% predicted) [19].
DNA collection and genotyping
DNA collection and the genotyping protocol of the Vlagt-
wedde/Vlaardingen study have been described previously
[16]. We genotyped functional SNPs G-1607GG in MMP1,
C-1306T in MMP2, A-82G and Asn357Ser (A/G) in
MMP12. No tagging SNPs are known for TIMP1,t h e r e f o r e
we decided to genotype two noncoding SNPs, previously
associated with asthma [15]. Phe124Phe (T/C) and Ile158Ile
(C/T) in TIMP1.I nTIMP2, we genotyped G-418C. With
Haploview, using genotype data from the HapMap project
[20,21]we selected 3 haplotype tagging SNPs for MMP9
that tag haplotypes with a frequency above 5% in MMP9
including 5 kb flanking regions at both the 3’UTR and
5’UTR: rs6065912, rs3918278 and rs8113877. Characteris-
tics of the genotyped SNP are presented in table 2
The SNPs that were significantly associated with excess
FEV1 decline or COPD development in the Vlagtwedde/
Vlaardingen population were genotyped in the Doe-
tinchem cohort by KBioscience http://www.kbioscience.co.
uk using a patent-protected system (KASPar). We used
the statistical software R, “genetics” package (version 1.9.1)
to determine whether the SNPs were in Hardy Weinberg
equilibrium and linkage disequilibrium.
Statistics
All TIMP1 analyses were stratified according to sex, since
this gene is located on the X-chromosome. To investigate
the effect of SNPs on annual FEV1 decline in the Vlagt-
wedde/Vlaardingen cohort, we used Linear Mixed Effect
(LME) models with adjustment for potential confounders
(i.e. sex, first FEV1 after age 30 years, pack-years) using a
general genetic model (see additional file 1) [16,22]. We
tested whether there was an interactive effect of TIMP1
and MMP SNPs on FEV1 d e c l i n eb yi n t r o d u c i n gt h e i ri n t e r -
action term into the model. We used ANOVA and linear
regression models to study SNP effects on first and last
available FEV1 and FEV1/VC (adjusted for sex, age, pack-
years, and height in regression models). Differences in gen-
otype frequencies of single SNPs for all genes and addition-
ally haplotype frequencies in MMP9 between subjects with
and without COPD were tested using Chi-square tests.
T h eS N P st h a tw e r es i g n i ficantly associated with
excess FEV1 decline or COPD development in the
Vlagtwedde/Vlaardingen population (p values < 0.05;
tested 2-sided) were genotyped in the Doetinchem
cohort for verification. FEV1 decline in the Doetinchem
cohort was calculated based on FEV1 decline between
the two surveys and genotype effects were tested using
linear regression analyses, adjusted for sex, age, pack-
years and baseline FEV1
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sion 14.0.1 for Windows), S-Plus (version 7), the statisti-
cal package R (version 1.9.1) [23]. and Chaplin [24,25].
Results
Allelic frequencies for the minor alleles of the MMP and
TIMP SNPs in the Vlagtwedde/Vlaardingen cohort were
comparable to those reported in the NCBI dbSNP data-
base: MMP1 G-1607GG 0.51, MMP2 C-1306T 0.27,
MMP9 rs3918278 0.03, MMP9 rs6065912 0.12, MMP9
rs8113877 0.40, MMP12 A-82G 0.15, MMP12 Asn357-
Ser 0.03, TIMP1 Ile158Ile in males 0.01, in females 0.01,
and TIMP1 Phe124Phe in males 0.50, and in females
0.53. All SNPs were in Hardy Weinberg equilibrium.
The SNPs in MMP9 were in high LD (r
2 >0.8).
Association of MMP SNPs in Vlagtwedde/Vlaardingen
MMP2 C-1306T was significantly associated with accel-
erated longitudinal decline in FEV1 in the total
population (TT-genotype -4.0 ml/yr excess decline com-
pared to CC-genotype, p = 0.027, figure 1), and was also
associated with a lower mean FEV1 % predicted (CC:
92.5, CT: 93.5, TT: 88.5% predicted; p = 0.013) at the
last survey. This association remained significant after
adjustment for packyears of smoking in linear regression
models. SNPs in MMP1, MMP12 and SNPs and haplo-
types in MMP9 were not significantly associated with
longitudinal FEV1 decline, level of lung function or pre-
sence of COPD (GOLD stage ≥ II) (table 3), although
power was limited for the latter. Since smoking upregu-
lates MMP activity [26]. we also analyzed FEV1 decline
with respect to interaction of the SNPs and smoking.
These interaction-terms were not significant.
Association of TIMP1 SNPs in Vlagtwedde/Vlaardingen
The TIMP1 Phe124Phe SNP was associated with excess
FEV1 decline in males only (-4.2 ml/yr excess FEV1
decline compared to wild type (p = 0.041, figure 2). We
Table 1 Characteristics of the Vlagtwedde/Vlaardingen and Doetinchem cohorts
Vlagtwedde/Vlaardingen N = 1390 Doetinchem N = 1152
Age at last survey, yrs 52 (35-79) 50 (31-71)
Males, % 51 47
Pack-years 9.0 (0-262.1) 5 (0-84)
Never smokers, n (%) 445 (32.0) 371 (32.2)
last FEV1%pred* 93.5 (36.0-138.1) 106.6 (39.1-150.7)
ΔFEV1, ml/yr
† -21.1 (-121;155) -28.7 (-292; 130)
FEV1 values, n 7 (1-8) 2 (2-2)
Yrs of follow-up 21 (0-25) 5 (5-5)
GOLD stage > II,n (%) 186 (13.4) 37 (3.2)
Data are presented as median (range).
* FEV1 % predicted at the last surveys of Vlagtwedde/Vlaardingen cohort (1989/1990) and the Doetinchem cohort (1999-2003).
† calculated as last-first FEV1/years participated.
Table 2 Characteristics of the genotyped SNPs
SNP name rs
number
Chromosome
position of gene
Functionality
MMP1 G-1607GG rs1799750 11q22-q23 G-insertion generates a new 5’-GGA-3’ core recognition sequence for members of the ETS
family of transcription factors
MMP2 C-1306T rs243865 16q23 T-allele disrupts a Sp1 binding site, thereby lowering the promoter activity approximately
twofold in macrophages and epithelial cells
MMP9 rs6065912 rs6065912 20q11.2-13.1 tagging SNP for MMP9 gene
MMP9 rs3918278 rs3918278 tagging SNP for MMP9 gene
MMP9 rs8113877 rs8113877 tagging SNP for MMP9 gene
MMP12 A-82G rs2276109 11q22.2-22.5 A-allele has higher affinity for transcription factor AP-1 and and higher gene expression in
reporter gene assays
MMP12 Asn357Ser rs652438 located in the coding region of the hemopexin domain that is responsible for MMP12
activity, while the function of this polymorphism remains unknown
TIMP1 Phe124Phe rs4898 Xp11.3-11.23 unknown
TIMP1 Ile158Ile rs11551797 unknown
TIMP2 G-418C
Abbreviations: SNP Single Nucleotide Polymorphism; MMP Matrix Metallo Protease; TIMP Tissue Inhibitor of MMP; ETS E26 transformation-specific; Sp1
Stimulating Protein 1; AP-1 Activator Protein-1
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excess longitudinal FEV1 decline in both males and
females (-30.7 ml/yr respectively -9.5 ml/yr excess FEV1
d e c l i n ec o m p a r e dt ow i l dt y p e ,p=0 . 0 0 1a n dp=0 . 0 3 1
respectively, figure 2). The minor allele of the Ile158Ile
SNP was more prevalent in females with COPD than
without COPD: CT genotype, 6.5% and 1.5% respectively,
p = 0.051 (table 4). The TIMP1 Phe124Phe SNP was not
associated with COPD, although power to detect such an
association was low. SNPs in TIMP1 were not associated
with level of lung function cross-sectionally.
Interaction of TIMP1 and MMP genes on FEV1 decline in
Vlagtwedde/Vlaardingen
We found significant associations of TIMP1 and MMP2
SNPs with FEV1 decline. To test for interaction between
these genes, we included interaction terms of TIMP1
and MMP2 SNPs in our models on FEV1 decline, and
stratified the analyses by sex. These interaction terms
were not significant.
Replication of significant findings in an independent
population cohort
To investigate whether results were not found due to
chance, we analyzed genes that were significantly
associated with FEV1 level or decline in the Vlagtwedde/
Vlaardingen cohort, i.e. MMP2 and TIMP1,i na ni n d e -
pendent cohort of the general population. Genotype fre-
quencies in the Doetinchem population were similar and
not statistically different from the Vlagtwedde/Vlaardin-
gen population (table 5). The TIMP1 Phe124Phe SNP
was associated with excess FEV1 decline in males (T
allele -7.6 ml/yr compared to wild type, p = 0.10), simi-
larly to the findings in the Vlagtwedde/Vlaardingen
cohort, although with lower significance. In contrast to
the findings in Vlagtwedde/Vlaardingen, TIMP1 Ile158Ile
was not associated with excess decline, but with less
FEV1 decline in females (42.9 ml/yr less decline com-
p a r e dt ow i l dt y p e ,p=0 . 0 0 8 ) ,b u tn o ti nm a l e s .T h e
MMP2 C-1306T was not significantly associated with
excess FEV1 decline or lower FEV1% predicted in the
Doetinchem cohort.
To increase the power of the studies, we additionally
tested for association for COPD development and
FEV1% predicted in pooled analyses of the Vlagtwedde/
Vlaardingen and Doetinchem cohorts. We only found a
significant association for COPD with TIMP1 Ile158Ile
in females (OR = 4.3, 95% CI = 1.2-15.3, p = 0.015),
similar as the observation in Vlagtwedde/Vlaardingen
alone but with stronger significance.
Figure 1 Effect of SNPs in MMP genes on longitudinal decline in FEV1. Mean adjusted declines in FEV1 (in ml/yr) are shown per genotype;
bars represent 95% confidence intervals.
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Our study is the first to show that one SNP in TIMP1
predicts excess FEV1 decline in two independent popu-
lations, albeit not quite reaching conventional statistical
significance in the replication cohort. In the initial
cohort we additionally found an association of MMP2
with FEV1 decline, but this was not replicated in the
second independent population, indicating that the role
of genetic variation in MMP2 on rate of FEV1 decline is
still debatable. In contrast to previous reports on case-
control studies that showed an association of MMP1,
MMP9 and MMP12 with COPD, emphysema, decreased
levels of FEV1, and/or excess decline in FEV1 [12,14].,
we found no indication whatsoever for a role of MMP1,
MMP9 or MMP12 in the development of (mild to
moderate) COPD or FEV1 decline in our prospective
population studies. Consequently, our data suggest that
the imbalance in MMPs and TIMPs is likely not dis-
turbed due to genetic variations in MMP genes. This
d o e sn o tr u l eo u tt h a tM M P sp l a yar o l ei nC O P D
development at all. Genetic variations in genes involved
in regulation of MMPs and TIMPs levels, such as inter-
leukin(IL)-10, IL-13, epithelial growth factor (EGF) and
tumor necrosis factor-a (TNF-a) [27,28]may clearly
influence the imbalance of MMPs and TIMPs in COPD.
Future studies are needed that address the effect of
these genes on FEV1 decline in the general population.
We show for the first time that genetic variation in
TIMP1 may accelerate the normally occurring FEV1
decline in the general population. We found that the
Table 3 MMP SNPs and development of COPD in Vlagtwedde/Vlaardingen (GOLD stage ≥ II)
SNP No COPD N (%) COPD N (%) P value SNP No COPD N (%) COPD N (%) P value
MMP1 G-1607GG G 295 (26.4) 44 (24.7) 0.845 MMP9 rs6065912 TT 873 (77.0) 145 (80.1) 0.576
G&GG 565 (50.6) 94 (52.8) TC 245 (21.6) 18 (33.2)
GG 257 (23.0) 40 (22.5) CC 16 (1.4) 3 (1.7)
MMP2 C-1306T CC 609 (52.8) 103 (55.4) 0.180 MMP9 rs8113877 TT 408 (35.8) 76 (40.6) 0.137
CT 466 (40.5) 65 (34.9) TC 559 (49.0) 77 (41.2)
TT 77 (6.7) 18 (9.7) CC 174 (15.2) 34 (18.2)
MMP12 Asn357Ser AA 1054 (93.1) 171 (94.0) 0.673 MMP9 rs3918278 GG 1078 (94.7) 177 (96.7) 0.122
AG 78 (6.9) 11 (6.0) GA 59 (5.2) 5 (2.7)
GG 0 (0) 0 (0) AA 1 (0.1) 1 (0.6)
MMP12 A-82G AA 812 (72.2) 130 (71.4) 0.831
AG 281 (25.0) 48 (26.4)
GG 32 (2.8) 4 (2.2)
Figure 2 Effect of SNPs in TIMP1 on longitudinal decline in FEV1, stratified by sex. Mean adjusted declines in FEV1 (in ml/yr) are shown per
genotype; bars represent 95% confidence intervals.
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FEV1 decline in males only. Of importance, this associa-
tion was replicated in the Doetinchem cohort with a lar-
ger genotype effect (-9.0 ml/yr and -4.2 ml/yr excess
FEV1 decline in Doetinchem and Vlagtwedde/Vlaardin-
gen respectively), but with somewhat lower significance
(p values 0.10 and 0.04 respectively). Since the TIMP1
gene is located on the X-chromosome, carriage of one
mutant allele may already account for an effect in
males, whereas one mutant allele may be compensated
by the other allele in females. However, another
mechanism has to play a role since females homozygous
for the mutant allele have a similar decline as heterozy-
gous carriers.
Since the Phe124Phe SNP is a synonymous mutation
and therefore unlikely having a functional effect on pro-
tein structure or function, it should be regarded as a
marker for genetic variation in TIMP1. Future studies
are warranted to identify SNPs that have a functional
effect in this gene. Such SNPs may alter TIMP1 protein
structure, resulting in an altered/diminished affinity for
MMP9 and subsequently excess MMP9 activity leading
to parenchymal destruction.
We observed opposite effects of the TIMP1 Ile158Ile
SNP in the two populations under study. The SNP was
associated with excess FEV1 decline in both females and
males in Vlagtwedde/Vlaardingen, and with less FEV1
decline in females, without an effect in males in the
Doetinchem cohort. The SNP has a very low prevalence
and therefore type I errors can easily occur. By testing
the SNP in an independent population, we can conclude
that the significant effect in the Vlagtwedde/Vlaardingen
population is possibly found by chance.
The MMP2 C-1306T genotype effect on FEV1 decline
is small in the Vlagtwedde/Vlaardingen cohort, but we
observed no effect at all in the Doetinchem cohort,
which may indicate that the association in Vlagtwedde/
Vlaardingen may possibly be a spurious result that is
not relevant on a population level. On the other hand,
we can not completely rule out a genetic effect of
MMP2 since the power to detect small genotype effects
on longitudinal lung function decline is much larger in
Table 4 TIMP1 SNPs and development of COPD in Vlagtwedde/Vlaardingen (GOLD stage ≥ II), stratified by sex
FEMALES MALES
No COPD N (%) COPD N (%) P value No COPD N (%) COPD N (%) P value
TIMP1 Ile158Ile CC 572 (98.5) 43 (93.5) 0.051 TIMP1 Ile158Ile C 533 (98.9) 130 (99.2) 0.724
CT 9 (1.5) 3 (6.5) T 6 (1.1) 1 (0.8)
TT 0 (0) 0 (0)
TIMP1 Phe124Phe TT 122 (21.1) 12 (25.0) 0.298 TIMP1 Phe124Phe T 264 (50.4) 60 (45.8) 0.348
TC 308 (53.2) 20 (41.7) C 260 (49.6) 71 (54.2)
CC 149 (25.7) 16 (33.3)
Table 5 Genotype distribution of MMP2 and TIMP1 SNPs in Vlagtwedde/Vlaardingen and Doetinchem
Vlagtwedde/Vlaardingen
N (%)
Doetinchem N
(%)
P
value
MMP2 C-
1306T
CC 734 (53.0) 609 (55.1) 0.055
CT 552 (39.9) 443 (40.1)
TT 98 (7.1) 53 (4.8)
FEMALES MALES
Vlagtwedde/Vlaardingen
N (%)
Doetinchem N
(%)
P
value
Vlagtwedde/Vlaardingen
N (%)
Doetinchem N
(%)
P
value
TIMP1
Ile158Ile
CC 636 (98.0) 602 (99.2) 0.079 TIMP1
Ile158Ile
C 686 (99.0) 526 (99.4) 0.394
CT 13 (2.0) 5 (0.8) T 7 (1.0) 3 (0.6)
TT 0 (0) 0 (0)
TIMP1
Phe124Phe
TT 138 (21.3) 135 (23.4) 0.657 TIMP1
Phe124Phe
T 336 (49.6) 240 (47.6) 0.494
TC 338 (52.0) 295 (51.1) C 341 (50.4) 264 (52.4)
CC 173 (26.7) 147 (25.5)
TIMP1 SNP distributions are stratified by sex.
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stantial longer follow-up time than in Doetinchem [29].
This may explain the lack of replication. Further studies
with comparable power as in Vlagtwedde/Vlaardingen
are warranted to elucidate the role of MMP2 in FEV1
decline in the general population.
MMP9 SNPs were not associated with development of
COPD or FEV1 decline in our study. We did not genotype
the MMP9 C-1562T SNP that was previously associated
cross-sectionally with the presence of emphysema or
COPD in Japanese and Chinese individuals in a case-con-
trol study [13,14]due to technical problems. Therefore, we
cannot rule out a genetic role of MMP9 in COPD develop-
ment. However, we tagged the whole MMP9 gene for hap-
lotypes with a frequency above 10%, and found strong LD
in the whole region. We are therefore confident that we
also tagged the C-1562T SNP and that we did not miss
information. Alternatively, the causative factor for higher
levels of MMP9 in COPD lung tissue can be due to their
transcriptional upregulation by other cytokines involved in
COPD [30,31]It is therefore of interest to analyze SNPs in
these genes in the future as well.
We did not confirm associations of the MMP1 and
MMP12 SNPs and lung function decline as previously
described by Joos et al and Hunninghake et al [11,12]
However, in the first study the MMP12 Asn357Val SNP
was only associated with rate of decline in FEV1 in com-
bination with the MMP1 G-1607GG SNP. We per-
formed the same type of analyses and found no
association. Since Hunninghake et al found associations
of MMPs and lung function in smokers, we also per-
formed such stratified analyses according to smoking,
but found no associations in the ever or current
smokers.
Although the role of MMPs in COPD pathogenesis
has clearly been demonstrated, we are the first to ana-
lyze the effects of SNPs in a cohort of the general popu-
lation, whereas previous studies have used case-control
designs. Moreover, differences in phenotypes make the
comparison of our study and previous studies difficult.
For example, several studies have investigated the effect
of the C-1562T SNP in MMP9 in smokers and nonsmo-
kers with respect to emphysematous phenotypes using
chest CT scans [13,14,30]. We do not have CT scans
available in Vlagtwedde/Vlaardingen or in Doetinchem,
so we can not assess such genetic effects since pulmon-
ary function tests are not very sensitive to detect (mild)
emphysema [31].
Since the selection of our SNPs was hypothesis-driven,
and we tested only 9 SNPs, we feel that a correction for
multiple testing is not warranted, moreover since the
strength of the current study lies in the replication of
significant findings of one cohort in a second cohort.
We feel we did not miss any clinically relevant
associations of greater than 5 ml/year excess FEV1
decline due to lack of power. For example: we had
approximately 1000 subjects with the wild type genotype
of the rs8113877 in MMP9 and on average a mean
annual decline in FEV1 of 17 ml/yr which results in a
80% power to detect an excess decline of 5.5 ml/yr in
FEV1 in mutant carriers (n = 300), assuming a SD of 30
(derived from the actual SE = 1.166) in both groups.
However, we may have missed associations of MMP
SNPs with COPD, since we only had 40% power to
detect an OR of 1.5, assuming a risk allele frequency of
0.25.
Conclusions
Our study shows that genetic variation in TIMP1 is
associated with excess FEV1 decline in two independent
general populations, reaching moderate significance.
Further research is needed to assess the functionality of
this finding. We could not confirm a role for MMP
SNPs in excess FEV1 decline and COPD development in
the general population, although our study had sufficient
power to detect genetic effects. Since SNPs in MMP do
not appear to contribute to COPD, it is of interest to
assess the genetic contribution of MMP modifying
genes, like IL-10, IL-13, EGF, and TNF-a that regulate
transcription of MMPs.I na d d i t i o n ,S N P si no t h e r
TIMPs,s u c ha sTIMP2, may also affect the MMP-TIMP
balance and thereby exert an effect on FEV1 decline in
the general population.
Additional material
Additional file 1: This manuscript contains an online supplement
with additional methods.
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